Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotatercept in children with pulmonary arterial hypertension on standard of care
2023-504861-22-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- May 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 2, open-label, single-arm trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Merck & Co. Primary endpoints: Serum trough concentration of sotatercept, Area under the curve at steady state of sotatercept and 10 more. Planned start May 2023; status: authorised.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2023-504861-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504861-22-00.